A Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273 Vaccine in Adolescents 12 to <18 Years Old to Prevent COVID-19
Completed · Phase 2, Phase 3 · NCT04649151
Conditions: SARS-CoV-2
At a glance
- Research payments reported, 2025
- $1.6M
- U.S. investigators named
- 20
- Sites paid
- 14
- Planned or actual enrollment
- 4,328
About the trial
- Sponsor
- ModernaTX, Inc. (with Biomedical Advanced Research and Development Authority)
- Tested
- mRNA-1273 (biological), Placebo (biological), mRNA-1273.222 (biological)
- Dates
- Started 2020-12-09; completion 2024-06-14
- Results posted
- Yes
The mRNA-1273 vaccine is being developed to prevent COVID-19, the disease resulting from Severe Acute Respiratory Syndrome coronavirus (SARS-CoV-2) infection. The study is designed to primarily evaluate the safety, reactogenicity, and effectiveness of mRNA-1273 vaccine administered as primary series and a booster dose (BD) to an adolescent population. The study will also evaluate the safety and immunogenicity of an mRNA-1273.222 vaccine against the SARS-CoV- 2 omicron variant as a primary series.
From ClinicalTrials.gov, last updated 2025-09-15. Full record, eligibility and contacts (opens in a new tab)
Industry funding
ModernaTX, Inc. reported $1.6M in research payments for this study in 2025 (86 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Gary K. Boone, M.D. Family Medicine · San Diego, CA
- Salma H. Elfaki, MD Pediatrics · Orlando, FL
- Joseph G. Surber, DO Family Medicine · Columbus, GA
- Robert J. Buynak, M.D. Internal Medicine · Valparaiso, IN
- Scott P. Striplin, M.D. OB-GYN (Obstetrics & Gynecology) · Covington, LA
- Katherine F. Ruiz-de-luzuriaga, M.D. Pediatric Infectious Disease · Worcester, MA
- Gary D. Berman, M.D. Allergy & Immunology · Minneapolis, MN
- Brandon J. Essink, M.D. Family Medicine · Creighton, NE
- Frank Eder, MD Family Medicine · Binghamton, NY
- Seref Bornovali, MD Internal Medicine · Loveland, OH
- Carl P. Griffin, M.D. Family Medicine · Oklahoma City, OK
- Robert A. Clifford, M.D. Pediatrics · Charleston, SC
- John B. Etheridge, MD Pediatrics · Port Royal, SC
- Kashif R. Ali, M.D. Pediatrics · Houston, TX
- Madhavi Ampajwala, M.D Family Medicine · Frisco, TX
- Douglas S. Denham, D.O. Family Medicine · San Antonio, TX
- Kenneth O. Etokhana, M.D Pediatrics · San Antonio, TX
- Celia Reyes-acuna, M.D. Specialist · Corpus Christi, TX
- Judith L. Kirstein, M.D. Family Medicine · West Jordan, UT
- Barbara E. Rizzardi, MD Internal Medicine · Sandy, UT
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- South Texas Clinical Research $421,387
- Velocity Clinical Research Inc $242,246
- Dynamed Clinical Research LP $195,844
- Lynn Health Science Institute $154,080
- Coastal Pediatric Research $128,041
- University Clinical Research Deland LLC $105,727
- Paradigm Clinical Rsrch Center Inc $96,142
- Marwah Investments Corporation $83,981
- Clinical Research Institute Inc $61,236
- Tekton Research LLC $49,633
- Coastal Carolina Research Center LLC $18,298
- University of Massachusetts Medical School $5,915
- Cr Services Acquisition US LLC $2,130
- Clinical Trials of Texas Inc $2,000
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.